# A Safety and Immunogenicity Trial of IHV01

> **NCT02756208** · PHASE1 · COMPLETED · sponsor: **University of Maryland, Baltimore** · enrollment: 65 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **BIOLOGICAL:** 300 ug FLSC vaccine
- **BIOLOGICAL:** 150 ug FLSC vaccine
- **BIOLOGICAL:** 75 ug FLSC vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02756208
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2018-07
- **Final completion:** 2018-07
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2021-12-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02756208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02756208, "A Safety and Immunogenicity Trial of IHV01". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02756208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*